← Browse by Condition
Medical Condition

hidradenitis suppurativa hs

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for hidradenitis suppurativa hs sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hidradenitis suppurativa hs Clinical Trials

How many clinical trials are currently recruiting for hidradenitis suppurativa hs?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for hidradenitis suppurativa hs, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hidradenitis suppurativa hs?
hidradenitis suppurativa hs research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hidradenitis suppurativa hs clinical trial?
Eligibility criteria for hidradenitis suppurativa hs trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Novartis Pharmaceuticals 1 trial
Navigator Medicines, Inc. 1 trial
Sonoma Biotherapeutics, Inc. 1 trial

Recruiting Clinical Trials

NCT06785779
Recruiting
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
Enrollment
77 pts
Location
Saudi Arabia
Sponsor
Novartis Pharmaceuticals
View Trial →
NCT07384975 Phase 2
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
Enrollment
150 pts
Location
United States
Sponsor
Navigator Medicines, Inc.
View Trial →
NCT07123038
Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
Enrollment
36 pts
Location
United States
Sponsor
Sonoma Biotherapeutics, Inc.
View Trial →

Related Conditions

rheumatoid arthritis ra (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology